Iomeron (Iomeprol)

Iomeprol contains iodine atoms attached to a water‑soluble, non‑ionic backbone. When injected, the iodine absorbs X‑ray photons, increasing attenuation of the X‑ray beam and creating areas of higher radiodensity. This difference in attenuation produces enhanced contrast on the radiograph, making anatomical structures more distinguishable.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient size, renal function and the route of administration. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal contrast while minimizing risk.

The safety of Iomeron in pregnancy and lactation has not been fully established. It should be used only if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, which generally offers a lower incidence of discomfort and adverse reactions compared with older high‑osmolality agents. Its physicochemical profile provides strong X‑ray attenuation while maintaining good tolerability, making it comparable to other modern agents such as iohexol or iopamidol.

Iomeron should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze. Inspect the vial for particulate matter or discoloration before use and discard if any abnormalities are observed.

Iomeron is administered by a qualified healthcare professional as a sterile solution for injection. It can be given intra‑arterially for vascular imaging, intra‑articularly for joint studies, or intrathecally for spinal canal evaluation. The injection technique and volume depend on the specific diagnostic procedure and patient factors.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and thyroid dysfunction due to iodine load. Prompt recognition and appropriate medical management are essential if any of these events occur.

Iomeron should be avoided in patients with known hypersensitivity to iodinated contrast media, severe renal insufficiency, uncontrolled thyroid disease, or in neonates and infants unless absolutely necessary. Clinicians should also exercise caution in patients receiving nephrotoxic drugs or those with a history of severe allergic reactions.